Table of Content

1 INTRODUCTION 
    1.1 OBJECTIVES OF THE STUDY 
    1.2 MARKET DEFINITION  
    1.3 MARKET SCOPE  
    1.4 CURRENCY 
    1.5 MARKET STAKEHOLDERS  
    1.6 SUMMARY OF CHANGES 
           1.6.1 RECESSION IMPACT
2 RESEARCH METHODOLOGY 
    2.1 RESEARCH DATA 
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
    2.2 MARKET SIZE ESTIMATION 
    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 
    2.4 MARKET RANKING ANALYSIS 
    2.5 STUDY ASSUMPTIONS 
    2.6 RISK ASSESSMENT 
    2.7 LIMITATIONS 
    2.8 GROWTH RATE ASSUMPTIONS 
    2.9 RECESSION IMPACT ON BLOOD SCREENING MARKET 
3 EXECUTIVE SUMMARY 
4 PREMIUM INSIGHTS 
5 MARKET OVERVIEW 
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
           5.2.1 DRIVERS
           5.2.2 RESTRAINTS
           5.2.3 OPPORTUNITIES
           5.2.4 CHALLENGES
    5.3 PRICING ANALYSIS 
           5.3.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT
           5.3.2 AVERAGE SELLING PRICE TREND, BY REGION
    5.4 SUPPLY/VALUE CHAIN ANALYSIS 
    5.5 PORTER'S FIVE FORCES ANALYSIS 
    5.6 ECOSYSTEM ANALYSIS OF THE GLOBAL BLOOD SCREENING MARKET 
    5.7 TARIFF & REGULATORY LANDSCAPE 
           5.7.1 REGULATORY BODIES, GOVERNMENT AGENCIES & OTHER ORGANIZATIONS
    5.8 PATENT ANALYSIS 
    5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESS 
    5.10 KEY CONFERENCES & EVENTS IN 2023-2024 
    5.11 KEY STAKEHOLDERS & BUYING CRITERIA 
    5.12 TECHNOLOGY ANALYSIS 
    5.13 TRADE ANALYSIS 
           5.13.1 IMPORT SCENARIO 
           5.13.2 EXPORT SCENARIO 
    5.14 CASE STUDY ANALYSIS 
6 BLOOD SCREENING MARKET, BY PRODUCT & SERVICE 
    6.1 INTRODUCTION 
    6.2 REAGENTS & KITS 
           6.2.1 NAT REAGENTS & KITS
                    6.2.1.1 ENZYMES AND POLYMERASES
                    6.2.1.2 STANDARDS AND CONTROLS
                    6.2.1.3 PROBES AND PRIMERS
                    6.2.1.4 BUFFERS, NUCLEOTIDES & SOLUTIONS
                    6.2.1.5 LABELING & DETECTION REAGENTS
           6.2.2 ELISA REAGENTS & KITS
                    6.2.2.1 IMMUNOSORBENTS
                    6.2.2.2 CONTROLS
                    6.2.2.3 CONJUGATES
                    6.2.2.4 SUBSTRATES
                    6.2.2.5 SAMPLE DILUENTS & WASH SOLUTIONS
           6.2.3 OTHER REAGENTS & KITS
    6.3 INSTRUMENTS 
           6.3.1 RENTAL PURCHASE
           6.3.2 OUTRIGHT PURCHASE
    6.4 SOFTWARE & SERVICES 
8 BLOOD SCREENING MARKET, BY TECHNOLOGY  
    8.1 INTRODUCTION 
    8.2 NUCLEIC ACID TEST (NAT) 
           8.2.1 TRANSCRIPTION-MEDIATED AMPLIFICATION (TMA)
           8.2.2 REAL-TIME POLYMERASE CHAIN REACTION (RT-PCR)
    8.3 SEROLOGY/IMMUNOASSAY  
           8.3.1 CHEMILUMINESCENT IMMUNOASSAYS (CLIA)
           8.3.2 FLUORESCENT IMMUNOASSAYS (FIA)
           8.3.3 COLORIMETRIC IMMUNOASSAYS (CIA)/ ENZYME-LINKED IMMUNOASSAYS (ELISA)
    8.4 RAPID TESTS 
    8.5 WESTERN BLOT ASSAYS 
    8.6 NEXT-GENERATION SEQUENCING (NGS) 
9 BLOOD SCREENING MARKET, BY END USER 
    9.1 INTRODUCTION 
    9.2 BLOOD BANKS 
    9.3 HOSPITALS 
10 BLOOD SCREENING MARKET, BY REGION 
     10.1 INTRODUCTION 
     10.2 NORTH AMERICA 
             10.2.1 RECESSION IMPACT
             10.2.2 US
             10.2.3 CANADA
     10.3 EUROPE 
             10.3.1 RECESSION IMPACT
             10.3.2 GERMANY 
             10.3.3 UK
             10.3.4 FRANCE
             10.3.5 ITALY 
             10.3.7 SPAIN
             10.3.8 ROE
     10.4 ASIA PACIFIC 
             10.4.1 RECESSION IMPACT
             10.4.2 CHINA
             10.4.4 JAPAN
             10.4.5 INDIA
             10.4.6 AUSTRALIA
             10.4.7 ROAPAC
     10.5 LATIN AMERICA 
             10.5.1 RECESSION IMPACT
             10.5.2 BRAZIL
             10.5.3 MEXICO
             10.5.4 REST OF LATIN AMERICA
     10.6 MIDDLE EAST & AFRICA 
             10.6.1 RECESSION IMPACT
11 COMPETITIVE LANDSCAPE 
     11.1 INTRODUCTION 
     11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 
     11.3 MARKET SHARE ANALYSIS 
     11.4 REVENUE SHARE ANALYSIS 
     11.5 COMPANY EVALUATION MATRIX 
             11.5.1 STARS
             11.5.2 EMERGING LEADERS
             11.5.3 PERVASIVE PLAYERS
             11.5.4 PARTICIPANTS
             11.5.5 COMPANY FOOTPRINT
     11.6 START-UP/SME EVALUATION MATRIX 
             11.6.1 PROGRESSIVE COMPANIES
             11.6.2 RESPONSIVE COMPANIES 
             11.6.3 DYNAMIC COMPANIES 
             11.6.4 STARTING BLOCKS
             11.6.5 COMPETITIVE BENCHMARKING
     11.7 COMPETITIVE SCENARIO AND TRENDS 
             11.7.1 PRODUCT LAUNCHES & APPROVALS 
             11.7.2 DEALS
12 COMPANY PROFILES 
     12.1 KEY PLAYERS 
             12.1.1 F. HOFFMANN-LA ROCHE LTD.
             12.1.2 GRIFOLS
             12.1.3 THERMO FISHER SCIENTIFIC, INC.
             12.1.4 ABBOTT LABORATORIES
             12.1.5 BIO-RAD LABORATORIES, INC.
             12.1.6 REVVITY (EARLIER KNOWN AS PERKINELMER, INC.)
             12.1.7 BIOMÉRIEUX SA 
             12.1.8 MINDRAY
             12.1.9 SIEMENS HEALTHINEERS AG
             12.1.10 DANAHER CORPORATION (BECKMAN COULTER, INC)
     12.2 OTHER PLAYERS 
             12.2.1 DIASORIN
             12.2.2 BECTON, DICKINSON AND COMPANY
             12.2.3 QUIDELORTHO CORPORATION
             12.2.4 GE HEALTHCARE (WESTERN BLOTTING)
             12.2.5 MERCK MILLIPORE (WESTERN BLOTTING)
             12.2.6 BIO-TECHNE CORPORATION (WESTERN BLOTTING)
             12.2.7 TRINITY BIOTECH
             12.2.8 MACCURA BIOTECHNOLOGY CO., LTD.
             12.2.9 ENZO BIOCHEM, INC.
             12.2.10 J. MITRA & CO. PVT. LTD.
             12.2.11 GFE
             12.2.12 IMMUCOR, INC.
             12.2.13 CELLABS
             12.2.14 ABNOVA CORPORATION
             12.2.15 TULIP DIAGNOSTICS
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.
13 APPENDIX 
     13.1 DISCUSSION GUIDE 
     13.2 KNOWLEDGE STORE: MARKETSANDMARKET'S SUBSCRIPTION PORTAL 
     13.3 AVAILABLE CUSTOMIZATIONS 
     13.4 RELATED REPORTS 
     13.5 AUTHOR DETAILS 
Note:
Details on financials may not be captured in case of privately held companies that do not disclose their revenues in public domain.
Top 20-30 Companies in the market (Blood Screening Market) will be profiled. 
Market segmentation might be updated as per the research findings.
The market size will be given in terms of value (USD Million). The historical year considered for the study would be 2021, with base year as 2022, estimated year would be 2023 and forecast period would be 2023-2028.